


Surrey Heartlands Referral Criteria and Patient Pathway for Liraglutide 3.0mg (Saxenda®) treatment





Referral criteria for patients:

- they have a body mass index (BMI) of at least 35 kg/m2 (or at least 32.5 kg/m2 for members of minority ethnic groups known to be at equivalent risk of the consequences of obesity at a lower BMI than the white population) and
- they have non-diabetic hyperglycaemia (defined as a haemoglobin A1c level of 42 mmol/mol to 47 mmol/mol [6.0% to 6.4%] or a fasting plasma glucose level of 5.5 mmol/litre to 6.9 mmol/litre) and
- they have a high risk of cardiovascular disease and have conditions that would be improved by weight loss such as hypertension, obstructive sleep apnoea, hyperlipidaemia.
- Eligibility and treatment criteria: Adult patients who meet all bullet-points per criterion as defined in NICE TA664 (https://www.nice.org.uk/guidance/ta664/chapter/1-Recommendations)
- Saxenda 6 mg/mL solution for injection in pre-filled pen; Summary of Product Characteristics; https://www.medicines.org.uk/emc/product/2313#gref (last accessed 11.10.21)